Pfizer (PFE) Non-cash Items (2010 - 2011)
Pfizer (PFE) posted quarterly Non-cash Items of $751.0 million for Q4 2011, up 249.3% YoY from $215.0 million in Q4 2010, and up 249.3% sequentially from $215.0 million in Q4 2010.
Pfizer (PFE) Non-cash Items (2010 - 2011) Analysis & Trends
Pfizer has disclosed Non-cash Items across 2 years of filings, most recently posting $751.0 million for Q4 2011.
- In Q4 2011, Non-cash Items rose 249.3% year-over-year to $751.0 million; the TTM figure through Dec 2011 stood at $751.0 million (up 249.3% YoY), while the FY2011 annual figure was $751.0 million, up 249.3% from the prior year.
- Non-cash Items rose to $751.0 million in Q4 2011, from $215.0 million in the prior quarter.
- Over the last five years, Non-cash Items for PFE reached as high as $751.0 million in Q4 2011 and fell as low as $215.0 million in Q4 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2011 | 751.00 Mn |
| Dec 31, 2011 | 751.00 Mn |
| Dec 31, 2010 | 215.00 Mn |
| Dec 31, 2010 | 215.00 Mn |